Redwood secures funding for drug development
Redwood Bioscience has secured funding from Takeda Ventures to further develop its precision protein-chemical engineering platform for drug conjugate optimization. This funding will be applied to advancing Redwood's site specific protein modification technology for enhancing antibody-drug conjugates and peptide therapeutics.
"We are pleased that TVI has recognized the potential of Redwood's technology," said Karen Boezi, Redwood's CEO. "Their investment not only provides capital but access to experienced industry professionals at TVI and in the broader Takeda organization."